Avastin (bevacizumab) / Roche - LARVOL DELTA

Efficacy of liver transplantation after response to atezolizumab-bevacizumab downstaging of intermediate and advanced hepatocellular carcinoma (ImmunoXXL). (PubMed, J Hepatol) - P | "LT after Atezo-Bev is characterized by competitive RFS estimates in intermediate and advanced HCC presenting beyond transplant indications. Acute rejection seems increased but remains clinically manageable. LT should be considered after HCC response to immunotherapy."

Journal • Cardiovascular • Hematological Disorders • Hepatocellular Cancer • Oncology • Solid Tumor • Thrombosis • Transplant Rejection • Transplantation

The anti-tumor activity of BB-202, a novel anti-PD-1/anti-VEGF bispecific antibody (AACR 2026) - "In PD-1/PD-L1 blockade assays, BB-202 showed potency similar to pembrolizumab and substantially greater than AK112 and LM-299. BB-202 also blocked VEGFA activity with potency comparable to bevacizumab (Avastin), AK112, and LM-299...BB-202 is a potent, stable, and well-tolerated anti-PD-1/anti-VEGF bispecific antibody. Its superior in vitro potency and robust in vivo efficacy, together with a favorable developability profile, position BB-202 as a promising best-in-class therapeutic candidate among PD-1/VEGF-targeting bispecific antibodies."

Bispecific • Oncology

A first-in-human phase I study of TQB2922, an EGFR/C-MET bispecific antibody, as monotherapy and in combination with bevacizumab and chemotherapy in EGFR-mutant non-small cell lung cancer (ELCC 2026) - P1 | "Funding Chia Tai Tianqing Pharmaceutical Group Co. Ltd."

Bispecific • Combination therapy • First-in-human • Monotherapy • P1 data • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • MET

Targeting vascular endothelial growth factor and its receptors in non-small cell lung cancer for improved treatment strategies. (PubMed, J Recept Signal Transduct Res) - "Anti-angiogenic therapy, for instance, with monoclonal antibodies like bevacizumab and ramucirumab, as well as multi-targeted tyrosine kinase inhibitors (TKIs) like nintedanib and anlotinib has been shown to improve the management of NSCLC. Angiogenesis-associated biomarkers, despite extensive research, have not been seen to have a clinical impact in the management and treatment of NSCLC because of the heterogeneous characteristics and the dynamic regulation of the cascade. This review summarizes current VEGF/VEGFR-targeted therapies in NSCLC, mechanisms of resistance, and future directions toward biomarker-guided therapeutic optimization."

Journal • Review • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor

BIPHASIC KIDNEY INJURY DUE TO BEVACIZUMAB- AND DOXORUBICIN-ASSOCIATED RENAL-LIMITED THROMBOTIC MICROANGIOGRAPHY: A CASE REPORT (ISN-WCN 2026) - "It may be difficult to distinguish drug-induced TMA from other primary TMAs, and the principal treatment is withdrawal of the causative drug, which requires early recognition.Methods We report the case of a 52-year-old woman with metastatic ovarian serous adenocarcinoma who developed biphasic kidney dysfunction during chemotherapy with bevacizumab and pegylated liposomal doxorubicin (PLD). The patient was diagnosed with ovarian cancer nine years earlier and underwent hysterectomy, oophorectomy, colectomy, and adjuvant paclitaxel–carboplatin therapy...Recognition of characteristic renal histopathological findings is crucial in differentiating drug-induced TMA from other etiologies. Timely diagnosis allows prompt cessation of the offending drug, which may preserve kidney function and optimize patient outcomes during chemotherapy."

Case report • Clinical • Glomerulonephritis • Gynecology • Lupus Nephritis • Nephrology • Ovarian Cancer • Ovarian Serous Adenocarcinoma • Renal Disease • Solid Tumor

BEVACIZUMAB-ASSOCIATED KIDNEY TOXICITY IN ONCOLOGY PATIENTS: AN ONCONEPHROLOGY PERSPECTIVE FROM A MULTI-ETHNIC COHORT IN SOUTHEAST ASIA (ISN-WCN 2026) - "The coexistence of frequent toxicity and relatively prolonged survival highlights the importance of embedding onconephrology into cancer care. This study underscores the urgent need for structured surveillance, timely nephrology involvement, and prospective onconephrology research, aiming to develop predictive models and evidence-based guidelines to mitigate kidney complications and optimise outcomes in oncology populations."

Clinical • Chronic Kidney Disease • Colorectal Cancer • Diabetes • Diabetic Nephropathy • Heart Failure • Metabolic Disorders • Nephrology • Renal Disease • Solid Tumor

ACUTE TUBULAR INJURY WITH VACUOLIZATION AFTER PALBOCICLIB EXPOSURE IN A PATIENT WITH ADVANCED BREAST CANCER (ISN-WCN 2026) - "A 62-year-old woman with metastatic triple-positive breast cancer received paclitaxel, bevacizumab, and atezolizumab for two years to treat postoperative recurrence. CDK4/6 inhibition has been reported to impair autophagy, which may contribute to the observed tubular vacuolization and renal dysfunction. This case highlights a unique pattern of tubular injury potentially linked to autophagic disturbance caused by palbociclib."

Clinical • Metastases • Acute Kidney Injury • Breast Cancer • Fibrosis • Focal Segmental Glomerulosclerosis • Glomerulonephritis • Hormone Receptor Breast Cancer • Hormone Receptor Positive Breast Cancer • Immunology • Nephrology • Oncology • Renal Disease • Solid Tumor • CST3

A CASE OF LATE-ONSET NEPHROTIC-RANGE PROTEINURIA CAUSED BY AN ANTI-ANGIOGENIC THERAPY FOR METASTATIC BREAST CANCER (ISN-WCN 2026) - "After changing to epirubicin/cyclophosphamide (EC) regimen, the patient's condition had been rather stable after 6 courses of EC therapy, when nausea and general malaise developed and worsened. Then, the regimen was changed to weekly paclitaxel plus bevacizumab (PTX/BEV) therapy...Because it was considered Grade 3 adverse events due to anti-angiogenic therapy, BEV was discontinued and the patient was followed with azilsartan and dapagliflozin...Conclusion The adverse events due to anti-angiogenic therapy are reported to be high, with proteinuria (∼10% to 60%) and hypertension being most prevalent. The interval between initiation of the therapy and the onset of proteinuria varies significantly (several weeks to ∼1 year), but the present case exhibited apparent proteinuria after 80 weeks of therapy. It is important to continuously follow up with close attention to renal function and urinalysis during and after anti-angiogenic therapy, even when the patient has remained..."

Clinical • Metastases • Breast Cancer • Hypertension • Nephrology • Oncology • Renal Disease • Solid Tumor

RENAL ADVERSE EFFECTS OF ANTI-ANGIOGENIC AGENTS IN A TERTIARY HOSPITAL IN KENYA (ISN-WCN 2026) - "Nine patients (10.2%) developed proteinuria: eight were on bevacizumab and one on lenvatinib. These findings highlight the importance of close renal monitoring, early recognition of toxicity, and individualised management to maintain oncologic efficacy while preserving renal function. Larger multi-center studies are needed to confirm these findings in the African oncology populations."

Adverse events • Clinical • Acute Kidney Injury • Hypertension • Nephrology • Renal Disease

Reply to "IL-6 as a biomarker in atezolizumab plus bevacizumab in patients with hepatocellular carcinoma". (PubMed, J Gastroenterol) - No abstract available

Biomarker • Journal • Hepatocellular Cancer • Oncology • Solid Tumor • IL6

Real-world evaluation of bevacizumab plus platinum and paclitaxel for advanced cervical cancer: a single-arm study from Syria. (PubMed, Ecancermedicalscience) - "To evaluate the clinical effectiveness of bevacizumab with paclitaxel and either cisplatin or carboplatin in Syrian patients with metastatic or recurrent cervical cancer, using both median progression-free survival (PFS) and restricted mean survival time (RMST) analysis. The objective response rate reached 61.3%, compared to 48% in the reference trial. This study supports the effectiveness of bevacizumab-based therapy as a first-line option in the Syrian setting, showing sustained clinical benefit and reinforcing the relevance of international guidelines in local oncology practice."

HEOR • Journal • Real-world evidence • Cervical Cancer • Gynecologic Cancers • Oncology • Solid Tumor

A predictive model for treatment efficacy in RAS wild-type advanced colorectal cancer: development and external validation for EGFR inhibitor plus anti-angiogenic therapy based on a retrospective cohort. (PubMed, Sci Rep) - "This retrospective multi-center study included 600 RAS wild-type advanced CRC patients (development cohort: 420 patients from two centers; external validation cohort: 180 patients from an independent center) treated with EGFR inhibitors (cetuximab/panitumumab) plus anti-angiogenic agents (bevacizumab/fruquintinib/regorafenib) between 2018 and 2021. As a supplementary tool to current clinical guidelines, the model can partially address the problem of clinical response heterogeneity in combination therapy and provide simple decision support for clinicians in primary and secondary hospitals with limited detection conditions. However, the model has certain limitations in long-term prognostic prediction and needs to be further optimized and validated in larger, multi-center prospective cohorts before it can be translated into clinical practice of precision oncology."

Journal • Retrospective data • Tumor mutational burden • Colorectal Cancer • Oncology • Solid Tumor • CEACAM5 • TMB

Intra-arterial infusion of bevacizumab for the treatment of peritoneal metastatic high-grade renal cell carcinoma: a case report. (PubMed, Front Immunol) - "The patient then underwent first-line treatment with ICI (Immune Checkpoint Inhibitors) in combination with pezopanib for 9 months before progressing and then changing to second-line treatment with ICI in combination with axitinib for 2 months before progressing again. Subsequent systemic therapy was changed to everolimus combined with voronib targeted therapy until now, and the lesion has continued to shrink on multiple follow-ups in between. Abdominal arterial infusion of bevacizumab embolization provides a feasible local treatment option for peritoneal metastases in stage IV RCC, warranting further clinical exploration."

Journal • Genito-urinary Cancer • Oncology • Pain • Palliative care • Pancreatic Cancer • Renal Cell Carcinoma • Solid Tumor

First-line Nivolumab plus FOLFOXIRI/Bevacizumab in advanced RAS/BRAF-mutated colorectal cancer: efficacy, safety and biomarker discovery from the phase II NIVACOR trial. (PubMed, Nat Commun) - P2 | "Alterations in pathways such as PI3K/AKT, chemokine signaling and DNA repair showed correlation with treatment activity. These findings highlight the potential synergy between immune checkpoint inhibitors and cytotoxic chemotherapy in selected patients with pMMR/MSS mCRC."

Biomarker • IO biomarker • Journal • P2 data • Colorectal Cancer • Oncology • Solid Tumor • BRAF • RAS

Conversion therapy for advanced hepatocellular carcinoma following complete response to transarterial radioembolization combined with atezolizumab and bevacizumab. (PubMed, Radiol Oncol) - "In selected patients, combining transarterial radioembolization with systemic immunotherapy may enable conversion to surgical resection in advanced hepatocellular carcinoma, even with subthreshold tumor radiation doses, highlighting a potential synergistic and abscopal effect between locoregional and systemic therapies."

Journal • Cardiovascular • Hematological Disorders • Hepatitis C • Hepatocellular Cancer • Infectious Disease • Liver Cancer • Oncology • Solid Tumor • Thrombosis

Safety and efficacy of intrathecal pemetrexed and bevacizumab in non-small cell lung cancer (NSCLC) patients with leptomeningeal metastases (LM): protocol for a single-arm, prospective, phase Ia trial. (PubMed, BMJ Open) - P1 | "Trial results will be published in a peer-reviewed journal. NCT06663306, ClinicalTrials.gov."

Clinical protocol • Journal • P1 data • Genito-urinary Cancer • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor

Epigenetic activation of VEGFA by SMARCD1 mediates tumor progression and bevacizumab resistance in clear cell renal cell carcinoma. (PubMed, BMC Cancer) - No abstract available

Journal • Clear Cell Renal Cell Carcinoma • Genito-urinary Cancer • Oncology • Solid Tumor • SMARCD1 • VEGFA

Unclear territory: navigating metastatic nonclear cell renal cell carcinoma. (PubMed, Curr Opin Oncol) - "Therapeutic advances are reshaping the management of nccRCC, with IO/TKI regimens and histology-specific therapies showing promise. Continued integration of molecular classification, rare subtype-specific trials, and international collaboration will be essential to establish evidence-based treatment standards for this diverse and understudied population."

Journal • Genito-urinary Cancer • Kidney Medullary Carcinoma • Non Clear Cell Renal Cell Carcinoma • Oncology • Papillary Renal Cell Carcinoma • Renal Cell Carcinoma • Solid Tumor • ALK • FH

Evaluation of hyperprogressive disease with atezolizumab plus bevacizumab for hepatocellular carcinoma: A secondary analysis of the IMbrave150 trial. (PubMed, Int J Cancer) - "For all definitions of early progression/treatment failure, the risk was either significantly lower with atezolizumab plus bevacizumab than with sorafenib, or there were no differences. Atezolizumab plus bevacizumab treatment is unlikely to cause significant HPD."

Journal • Hepatocellular Cancer • Oncology • Solid Tumor • AFP

Efficacy and safety of IBI363 monotherapy or in combination with bevacizumab in patients with advanced colorectal cancer. (ASCO 2025) - P1 | "IBI363 monotherapy demonstrated prolonged overall survival in pts with advanced CRC compared to historic data of standard of care. IBI363 plus beva showed even more encouraging efficacy with acceptable safety and warrants further development."

Clinical • Combination therapy • IO biomarker • Metastases • Monotherapy • Colorectal Cancer • Endocrine Disorders • Microsatellite Instability • Musculoskeletal Pain • Oncology • Solid Tumor • KRAS • MSI • NRAS

Bevacizumab and Erlotinib in Hereditary and Sporadic Papillary Kidney Cancer. (PubMed, N Engl J Med) - P2 | "The combination of bevacizumab and erlotinib showed antitumor activity in patients with HLRCC-associated or sporadic papillary renal-cell carcinoma. Toxic effects were those known to be associated with this combination. (Funded by the National Cancer Institute and others; ClinicalTrials.gov number, NCT01130519.)."

Journal • Cardiovascular • Genetic Disorders • Genito-urinary Cancer • Hypertension • Kidney Cancer • Oncology • Papillary Renal Cell Carcinoma • Renal Cell Carcinoma • Renal Disease • Solid Tumor • FH

Combined treatment of durvalumab, bevacizumab and tremelimumab in subjects with hepatocellular carcinoma (HCC) or biliary tract carcinoma (BTC). (ASCO 2025) - P2 | "The combination of durvalumab, bevacizumab and tremelimumab did not meet its primary endpoint but demonstrated a clinically meaningful overall survival benefit. No new safety signals were seen."

Clinical • Anemia • Biliary Cancer • Biliary Tract Cancer • Gastroenterology • Gastrointestinal Disorder • Hepatocellular Cancer • Immunology • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Renal Cell Carcinoma • Solid Tumor

Efficacy and Safety of Avutometinib ± Defactinib in Recurrent Low-Grade Serous Ovarian Cancer: Primary Analysis of ENGOT-OV60/GOG-3052/RAMP 201. (PubMed, J Clin Oncol) - P3 | "The efficacy and safety profile of avutometinib in combination with defactinib support this combination as a potential standard of care for recurrent LGSOC. A randomized phase 3 study of avutometinib and defactinib versus investigator's choice of therapy for women with recurrent LGSOC is currently enrolling (RAMP301; ClinicalTrials.gov identifier: NCT06072781)."

Journal • Fibrosarcoma • Hematological Disorders • Oncology • Ovarian Cancer • Ovarian Serous Adenocarcinoma • Sarcoma • Solid Tumor • KRAS

Pembrolizumab vs placebo plus weekly paclitaxel ± bevacizumab in platinum-resistant recurrent ovarian cancer: Results from the randomized double-blind phase III ENGOT-ov65/KEYNOTE-B96 study (ESMO 2025) - P3 | "Grade ≥3 treatment-related adverse events occurred in 67.5% versus 55.3% of participants, respectively. Conclusions Pembrolizumab plus weekly paclitaxel ± bevacizumab showed statistically significant and clinically meaningful improvements in PFS regardless of PD-L1 status and in OS in PD-L1 CPS ≥1 PRROC, with a manageable safety profile."

Clinical • Late-breaking abstract • P3 data • Platinum resistant • Oncology • Ovarian Cancer • Peritoneal Cancer • Solid Tumor • PD-L1

IKF-035/ABC-HCC: A phase IIIb, randomized, multicenter, open-label trial of atezolizumab plus bevacizumab versus transarterial chemoembolization (TACE) in intermediate-stage hepatocellular carcinoma (ESMO 2025) - P3 | "The IMbrave150 phase 3 study showed that the combination of the anti-PD-L1 antibody atezolizumab and the anti-VEGF antibody bevacizumab (atezo/bev) extend survival compared to sorafenib in 1L treatment of advanced and intermediate HCC failing/unsuited for TACE. Conclusions The first IA provides important insights into the efficacy of atezo/bev vs. TACE in intermediate stage HCC. Based on these findings, the trial is progressing to the 2nd IA at 66% information time (169 events)."

Clinical • Late-breaking abstract • P3 data • Gastrointestinal Cancer • Hepatocellular Cancer • Oncology